Display options
Cite
De Flines J, Scheen AJ. Diabète sucré et décompensation cardiaque: spécificités ethiopathogéniques et thérapeutiques. [Diabetes mellitus and congestive heart failure: physiopathology and treatment]. Rev Med Suisse. 2006;2(76):1893-6, 1898-900
De Flines, J., & Scheen, A. J. (2006). Diabète sucré et décompensation cardiaque: spécificités ethiopathogéniques et thérapeutiques. [Diabetes mellitus and congestive heart failure: physiopathology and treatment]. Revue medicale suisse, 2(76), 1893-6, 1898-900.
De Flines, J, and Scheen, A J. "Diabète sucré et décompensation cardiaque: spécificités ethiopathogéniques et thérapeutiques." [Diabetes mellitus and congestive heart failure: physiopathology and treatment]. Revue medicale suisse vol. 2,76 (2006): 1893-6, 1898-900.
De Flines J, Scheen AJ. Diabète sucré et décompensation cardiaque: spécificités ethiopathogéniques et thérapeutiques. [Diabetes mellitus and congestive heart failure: physiopathology and treatment]. Rev Med Suisse. 2006 Aug 23;2(76):1893-6, 1898-900. French. PMID: 16972538.
Copy Download .nbib Format: NLM
Share it on

Rev Med Suisse. 2006 Aug 23;2(76):1893-6, 1898-900.

[Diabetes mellitus and congestive heart failure: physiopathology and treatment].

Revue medicale suisse

[Article in French]
J De Flines, A J Scheen

Affiliations

  1. Université de Liège Service de diabétologie, nutrition et maladies métaboliques Département de médecine interne CHU Sart'Tilman B-4000 Liège I.

PMID: 16972538

Abstract

Diabetes mellitus increases by 2.5 to 5 the relative risk of congestive heart failure. Besides the classical risk factors of congestive heart failure such as obesity, arterial hypertension and coronary artery disease that are frequently associated to type 2 diabetes, a diabetic cardiomyopathy plays also a role. This specific complication is related to metabolic factors and oxidative stress, leading to muscular cell apoptosis and fibrosis. The management of a diabetic patient with congestive heart failure has several specificities not only concerning the treatment of cardiac insufficiency but most importantly concerning antidiabetic therapy. The relationship between glitazones, peripheral oedema and risk of congestive heart failure is currently raising much interest and controversies.

MeSH terms

Publication Types